Ilya Tsimafeyeu/bucare.org
Jun 28, 2025, 06:35
Ilya Tsimafeyeu: Targeting Fibroblast Growth Factor Receptor 1 to Enhance the Efficacy of Immunotherapy
Ilya Tsimafeyeu, Director at the Bureau of Cancer Research, shared a post on Facebook:
“In this article, I explored a provocative question: could locking FGFR1 be the key to enhancing the power of immunotherapy?”
Title: Future perspectives: targeting fibroblast growth factor receptor 1 to enhance the efficacy of immunotherapy
Author: Ilya Tsimafeyeu
Read The Full Article at Open Exploration.
More posts featuring Ilya Tsimafeyeu on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Sep 4, 2025, 23:59
Sep 4, 2025, 20:03
Sep 4, 2025, 19:35
Sep 4, 2025, 16:17
Sep 4, 2025, 16:08
Sep 4, 2025, 15:59
Sep 4, 2025, 15:51